Dali Pharmaceuticalco.Ltd Management

Management criteria checks 4/4

Dali Pharmaceuticalco.Ltd's CEO is Jun Xiang Yang, appointed in Oct 2021, has a tenure of 3.08 years. directly owns 23.31% of the company’s shares, worth CN¥158.73M. The average tenure of the management team and the board of directors is 5.6 years and 10.3 years respectively.

Key information

Jun Xiang Yang

Chief executive officer

CN¥583.3k

Total compensation

CEO salary percentage	n/a
CEO tenure	3.1yrs
CEO ownership	23.3%
Management average tenure	5.6yrs
Board average tenure	10.3yrs

Recent management updates

Recent updates

Some Confidence Is Lacking In Dali Pharmaceuticalco.,Ltd (SHSE:603963) As Shares Slide 46%

Apr 22

Dali Pharmaceuticalco.,Ltd's (SHSE:603963) 29% Price Boost Is Out Of Tune With Revenues

Mar 08

CEO

Jun Xiang Yang (62 yo)

3.1yrs

Tenure

CN¥583,300

Compensation

Mr. Jun Xiang Yang has been General Manager at Dali Pharmaceutical Co., Ltd since October 12, 2021. Mr. Yang serves as Executive director and general manager at Dali Junkang Investment Co., Ltd. He has bee...

Leadership Team

Name	Position	Tenure	Compensation	Ownership
Jun Xiang Yang	Chairman of the Board & GM	3.1yrs	CN¥583.30k	23.31% CN¥ 158.7m
Shao Yun Li	Deputy GM	16.8yrs	CN¥347.70k	no data
Jun Wei Yang	Assistant GM	no data	CN¥236.50k	0.56% CN¥ 3.8m
Peirong Wu	Board Secretary	5.6yrs	CN¥236.50k	0.0046% CN¥ 31.0k

5.6yrs

Average Tenure

57yo

Average Age

Experienced Management: 603963's management team is seasoned and experienced (5.6 years average tenure).

Board Members

Name	Position	Tenure	Compensation	Ownership
Jun Xiang Yang	Chairman of the Board & GM	16.7yrs	CN¥583.30k	23.31% CN¥ 158.7m
Jun Wei Yang	Assistant GM	16.7yrs	CN¥236.50k	0.56% CN¥ 3.8m
Cui Xian Yin	Vice Chairman	4.3yrs	CN¥400.00k	3.06% CN¥ 20.8m
Wei Yuan	Director	4.3yrs	CN¥160.00k	no data
Li Hua Zeng	Vice Chairman of the Board	10.3yrs	CN¥240.00k	no data
Ji Yao Zeng	Director	9.4yrs	CN¥80.00k	no data
Xin Liu	Chairman of the Supervisory Board	10.3yrs	no data	no data
Zu Zhao	Member of the Supervisory Board	10.3yrs	no data	no data

10.3yrs

Average Tenure

58.5yo

Average Age

Experienced Board: 603963's board of directors are seasoned and experienced ( 10.3 years average tenure).

Dali Pharmaceuticalco.Ltd Management

Management criteria checks 4/4

Key information

Recent management updates

Dali Pharmaceuticalco.,Ltd, Annual General Meeting, May 16, 2024

Less than half of directors are independent

Less than half of directors are independent

Recent updates

Third quarter 2024 earnings released: CN¥0.035 loss per share (vs CN¥0.021 loss in 3Q 2023)

Dali Pharmaceuticalco.,Ltd to Report Q3, 2024 Results on Oct 31, 2024

Second quarter 2024 earnings released: CN¥0.031 loss per share (vs CN¥0.038 loss in 2Q 2023)

Dali Pharmaceuticalco.,Ltd to Report First Half, 2024 Results on Aug 30, 2024

New minor risk - Market cap size

Dali Pharmaceuticalco.,Ltd(SHSE:603963) dropped from Shanghai Stock Exchange Composite Index

First quarter 2024 earnings released: CN¥0.024 loss per share (vs CN¥0.012 loss in 1Q 2023)

Dali Pharmaceuticalco.,Ltd, Annual General Meeting, May 16, 2024

Some Confidence Is Lacking In Dali Pharmaceuticalco.,Ltd (SHSE:603963) As Shares Slide 46%

Dali Pharmaceuticalco.,Ltd to Report Q1, 2024 Results on Apr 26, 2024

Dali Pharmaceuticalco.,Ltd's (SHSE:603963) 29% Price Boost Is Out Of Tune With Revenues

Dali Pharmaceuticalco.,Ltd to Report Fiscal Year 2023 Results on Apr 26, 2024

New minor risk - Share price stability

Dali Pharmaceuticalco.,Ltd to Report First Half, 2023 Results on Aug 29, 2023

Less than half of directors are independent

Third quarter 2022 earnings released: CN¥0.014 loss per share (vs CN¥0.022 loss in 3Q 2021)

Second quarter 2022 earnings released: CN¥0.024 loss per share (vs CN¥0.006 loss in 2Q 2021)

First quarter 2022 earnings released: CN¥0.015 loss per share (vs CN¥0.001 profit in 1Q 2021)

Less than half of directors are independent

Third quarter 2021 earnings released: CN¥0.022 loss per share (vs CN¥0.02 profit in 3Q 2020)

Third quarter 2021 earnings released: CN¥0.022 loss per share (vs CN¥0.02 profit in 3Q 2020)

Second quarter 2021 earnings released: CN¥0.006 loss per share (vs CN¥0.006 profit in 2Q 2020)

First quarter 2021 earnings released: EPS CN¥0.001 (vs CN¥0.005 loss in 1Q 2020)

New 90-day low: CN¥7.59

New 90-day low: CN¥7.65

New 90-day low: CN¥8.12

Third quarter 2020 earnings released: EPS CN¥0.019

New 90-day low: CN¥8.20

Dali Pharmaceutical Co., Ltd to Report Q3, 2020 Results on Oct 30, 2020

New 90-day low: CN¥8.22

New 90-day high - CN¥10.20

First half earnings released

New 90-day high - CN¥9.42

Dali Pharmaceutical Co., Ltd to Report First Half, 2020 Results on Aug 19, 2020

CEO

Tenure

Compensation

Leadership Team

Average Tenure

Average Age

Board Members

Average Tenure

Average Age